While increasing evidence indicates that ITAM/ITIM-containing immune receptors (i.e., TREM2, CD33, and CD22) are critically involved in AD progression, we still lack in-depth knowledge of the intracellular signaling molecules employed by these immune receptors to influence neurodegenerative disease. This evidence concerns the gene CD22 and neurodegenerative disease.